Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Capital Expenditures (2016 - 2023)

Spyre Therapeutics (SYRE) has disclosed Capital Expenditures for 9 consecutive years, with -$2.1 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Capital Expenditures fell 206800.0% year-over-year to -$2.1 million, compared with a TTM value of -$2.1 million through Dec 2023, down 5536.84%, and an annual FY2022 reading of $38000.0, down 93.37% over the prior year.
  • Capital Expenditures was -$2.1 million for Q3 2023 at Spyre Therapeutics, down from $1000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $2.8 million in Q3 2020 and bottomed at -$2.1 million in Q3 2023.
  • Average Capital Expenditures over 5 years is $227142.9, with a median of $75000.0 recorded in 2019.
  • The sharpest move saw Capital Expenditures surged 2531.58% in 2020, then plummeted 206800.0% in 2023.
  • Year by year, Capital Expenditures stood at $38000.0 in 2019, then soared by 2531.58% to $1.0 million in 2020, then tumbled by 90.7% to $93000.0 in 2021, then crashed by 98.92% to $1000.0 in 2022, then tumbled by 206800.0% to -$2.1 million in 2023.
  • Business Quant data shows Capital Expenditures for SYRE at -$2.1 million in Q3 2023, $1000.0 in Q3 2022, and $37000.0 in Q1 2022.